- Conditions
- Heart Failure, Methamphetamine Use Disorder
- Interventions
- MUD Management (contingency management +/- adjunctive MUD pharmacotherapy), HF GDMT management
- Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 58
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Healthy
- Interventions
- Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets), Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Obesity
- Interventions
- Naltrexone and Bupropion Combination, Behavioral Weight Loss, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity, Overweight
- Interventions
- NB32, PBO, Weight Management Program
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 8,910 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 224
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 221 more
- Conditions
- Obesity, Smoking Cessation, Bariatric Surgery Patients
- Interventions
- Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy
- Drug · Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Nicotine Dependence, Overweight, Obesity
- Interventions
- NB32, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 3
- States / cities
- Encino, California • Los Alamitos, California • Newport Beach, California
- Conditions
- Binge-Eating Disorder, Obesity
- Interventions
- Cognitive-Behavioral Therapy (CBT), NB Medication (on-going from acute treatment)
- Behavioral · Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Stimulant Use, Relapse, Cognitive Function, ADHD
- Interventions
- Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
- Interventions
- Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
- Behavioral
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Obesity, Cardiovascular Diseases
- Interventions
- Naltrexone HCl/Bupropion HCl ER, Placebo
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 139
- States / cities
- Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more
- Conditions
- Methamphetamine-dependence, Methamphetamine Abuse
- Interventions
- extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
- Conditions
- Obesity & Overweight, Cardiometabolic Health Indicators
- Interventions
- GLP-1 dose reduction, non-GLP weight loss medication, Maintenance of GLP-1 dose, Resistance exercise regimen, Lifestyle/nutrition counseling
- Drug · Behavioral
- Lead sponsor
- Jing Luo
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Healthy Adult Male and Female Volunteers
- Interventions
- BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
- Drug
- Lead sponsor
- BioCorRx Pharmaceuticals Inc
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Obesity
- Interventions
- Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Methamphetamine Dependence
- Interventions
- placebo, Naltrexone and Bupropion SR
- Other · Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 21 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Binge-eating Disorder, Obesity
- Interventions
- NB medication (Naltrexone Bupropion combination), Behavioral Weight Loss (BWL) counseling, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Type 2 Diabetes, Obesity
- Interventions
- Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
- Other · Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Obesity
- Interventions
- Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, Overweight, Diabetes Mellitus, Type 2
- Interventions
- Naltrexone SR 32 mg/bupropion SR 360 mg/ day, Placebo, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 505 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 53
- States / cities
- Fairhope, Alabama • Peoria, Arizona • Phoenix, Arizona + 46 more
- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
- Interventions
- Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
- Behavioral · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, Overweight
- Interventions
- Naltrexone SR 16 mg/Bupropion SR 360 mg /day, Naltrexone SR 32 mg/Bupropion SR 360 mg /day, Placebo, Ancillary therapy
- Drug · Behavioral
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1,742 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 28 more
- Conditions
- Obesity, Overweight
- Interventions
- Behavioral Weight Loss (BWL), Early Responder: BWL continued, Early Non-responder: BWL continued with medication added
- Behavioral · Combination Product
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Obesity
- Interventions
- naltrexone and bupropion SR
- Drug
- Lead sponsor
- Orexigen Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 7
- States / cities
- San Diego, California • Augusta, Georgia • Lexington, Kentucky + 4 more
- Conditions
- Binge Eating Disorder
- Interventions
- Naltrexone and bupropion combination, Pill Placebo
- Drug · Other
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut